About Us

About the COVID-19 Prevention Network (CoVPN)

The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The CoVPN is comprised of the partners listed below.

Our Mission

To conduct Phase 3 efficacy trials for COVID-19 vaccines and monoclonal antibodies. The CoVPN will work to develop and conduct studies to ensure rapid and thorough evaluation of US government-sponsored COVID-19 vaccines and monoclonal antibodies for the prevention of COVID-19 disease.

HIV Vaccine Trials Network

The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.

HIV Prevention Trials Network

The HIV Prevention Trials Network (HPTN) develops and tests the safety and efficacy of non-vaccine interventions designed to prevent the transmission of HIV.

Infectious Disease Clinical Research Consortium

NIAID established the Infectious Diseases Clinical Research Consortium in 2019. It encompasses the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and a new leadership group.

AIDS Clinical Trials Group

The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world. These investigators and units serve as the major resource for HIV/AIDS research on treatment and care for persons living with HIV/AIDS.